Healthcare News Weekly Roundup | May 16–23, 2026

The week of May 16 to 23, 2026, delivered one of the most consequential stretches of healthcare news this year. The US Food and Drug Administration granted Enhertu two simultaneous approvals for HER2-positive early breast cancer, a decision that immediately repositioned the antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo as the most clinically versatile HER2-directed therapy on the market. With data from the DESTINY-Breast11 and DESTINY-Breast05 Phase 3 trials demonstrating a pathologic complete response rate of 67.3% in the neoadjuvant setting, versus 56.3% for the prior standard regimen, and a 53% reduction in the risk of invasive disease recurrence in the adjuvant setting, the clinical signal is the strongest the ADC field has produced in early-stage breast cancer to date.

This week’s top healthcare headlines at a glance:

1. FDA Grants Enhertu Twin Approval for HER2-Positive Early Breast Cancer
2. UK Introduces Health Bill to Abolish NHS England in Major Structural Overhaul
3. Bristol Myers Squibb and Hengrui Pharma Seal a $15.2 Billion Global Licensing Alliance
4. FDA Commissioner Marty Makary Resigns, Kyle Diamantas Named Acting Head
5. England Launches First Cross-Government Mental Health Strategy in 15 Years
6. Full-Life Technologies Closes $150 Million Series D for Radiopharmaceutical Pipeline
7. Revolution Medicines Confirms Phase 3 Win for Daraxonrasib in Pancreatic Cancer
8. UK Government Launches Fit Note Reform Pilots Covering 100,000 Appointments
9. Relay Therapeutics Posts Phase 2 Data for Zovegalisib in Rare Vascular Disorders
10. Accro Bioscience Secures $50 Million Series C for Ulcerative Colitis Program
11. Eli Lilly’s Oral GLP-1 Foundayo Reshapes Obesity Treatment Access
12. TGA Alerts Australia on ANDEXXA Removal and Peptide Product Safety Risks

FDA Grants Enhertu Twin Approval for HER2-Positive Early Breast Cancer

On May 15, 2026, the FDA approved fam-trastuzumab deruxtecan-nxki, marketed as Enhertu and co-developed by AstraZeneca and Daiichi Sankyo, for two distinct indications in adults with HER2-positive early-stage breast cancer. The neoadjuvant approval covers Stage II or III HER2-positive (IHC 3+ or ISH+) disease, where Enhertu is administered prior to surgery, followed by a taxane, trastuzumab, and pertuzumab (THP) regimen. The adjuvant approval addresses patients who have residual invasive disease after neoadjuvant HER2-targeted treatment, a population where recurrence risk has historically remained high despite the previous standard of care, trastuzumab emtansine (T-DM1).

The regulatory decisions rest on Phase 3 data from two separate trials. DESTINY-Breast11 demonstrated that patients receiving Enhertu followed by THP achieved a pathologic complete response rate of 67.3%, compared with 56.3% for those receiving dose-dense doxorubicin and cyclophosphamide followed by THP, an 11.2 percentage-point improvement. DESTINY-Breast05 found that Enhertu reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1 in the adjuvant setting. Both regulatory submissions were reviewed under Project Orbis, which enables concurrent oncology drug reviews across international regulatory partners, and DESTINY-Breast05 had previously received both Priority Review and Breakthrough Therapy Designation from the FDA.

The clinical and commercial stakes are substantial. AstraZeneca disclosed that the dual approval triggers a $155 million milestone payment to Daiichi Sankyo. For oncologists, the approvals expand Enhertu’s role across the entire HER2-positive breast cancer treatment continuum, from first presentation through metastatic disease, a span of indications that no other single HER2-directed therapy has achieved within such a compressed development timeline. Prescribing information carries a boxed warning for interstitial lung disease and pneumonitis, safety signals that treating physicians will need to monitor closely, particularly in the adjuvant setting where cumulative toxicity management carries long-term implications for quality of life. Rival ADC developers and T-DM1’s manufacturer Genentech, will be assessing how aggressively to defend remaining market share in the post-neoadjuvant setting.

Source: AstraZeneca Official Press Release | https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-two-her2-early-bc-settings.html

Source: FDA Drug Approval Notice | https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-two-separate-indications-fam-trastuzumab-deruxtecan-nxki-her2-positive-early-stage

UK Introduces Health Bill to Abolish NHS England in Major Structural Overhaul

The UK government introduced the Health Bill in the House of Commons on May 14, 2026, marking one of the most consequential pieces of NHS legislation since the Health and Social Care Act of 2012. The legislation’s central provision is the abolition of NHS England as a standalone arm’s-length body, with the majority of its commissioning functions transferring to the Secretary of State for Health and Social Care and to integrated care boards (ICBs) across England. The bill also mandates the creation of a single patient record system, removes mandatory local authority representation from ICB governance, and abolishes two further bodies: the Health Services Safety Investigations Body (HSSIB) and Healthwatch England.

The government framed the Health Bill as a mechanism for cutting bureaucracy and returning operational accountability closer to ministers and local health bodies. Accompanying the legislation is a wider reorganisation programme that includes ICB mergers, boundary realignments, and a mandated 50% reduction in ICB running costs. The impact assessment published alongside the bill asserted that most function transfers would have a neutral effect on patients and providers, on the basis that the same responsibilities would continue, simply under different organisational ownership.

That framing drew immediate critical scrutiny from health policy analysts. The Health Foundation’s Director of Policy and Research warned that the bill concentrated too much power in ministerial hands over what had been operationally independent functions, and expressed concern that removing mandatory local authority representatives from ICBs could weaken the connectivity between the NHS, social care, and public health at the local level at precisely the moment when integrated population health approaches are most needed. The single patient record provision, if implemented effectively, holds genuine promise for reducing clinical errors at care transitions, but its delivery timescales and technical architecture remain undefined in the bill’s current text. For NHS leaders, commissioners, and the private sector organisations operating across the NHS supply chain, the governance landscape has materially shifted, and the practical consequences of those shifts will take years to resolve.

Source: UK Department of Health and Social Care | https://www.gov.uk/government/organisations/department-of-health-and-social-care

Source: NHS Networks | https://networks.nhs.uk/blog/health-bill/

Bristol Myers Squibb and Hengrui Pharma Seal a $15.2 Billion Global Licensing Alliance

Bristol Myers Squibb and China’s Jiangsu Hengrui Pharma announced on May 12, 2026, that they had entered into a set of global strategic collaboration and licensing agreements covering 13 early-stage programs spanning oncology, haematology, and immunology. The potential total value of the agreement reaches approximately $15.2 billion, encompassing the exercise of options for jointly discovered programs and the achievement of development, regulatory, and commercial milestones across all programs. BMS will make near-term payments totaling up to $950 million to Hengrui, including a $600 million upfront cash payment, a $175 million first-anniversary payment, and a contingent second-anniversary payment of $175 million in 2028.

The structural architecture of the deal distinguishes it from most China-out licensing transactions. Four oncology and haematology assets originating from Hengrui will carry exclusive worldwide rights for BMS, except for mainland China, Hong Kong, and Macau. Four immunology assets originating from BMS will go to Hengrui for exclusive rights within those three markets. Five additional programs will be jointly discovered and developed using Hengrui’s discovery engine and platform technologies. Critically, Hengrui retains an option to co-develop and co-commercialise certain assets internationally alongside BMS, a concession that elevates this arrangement well beyond the standard licensing template and signals genuine confidence in Hengrui’s scientific and regulatory execution capabilities. The transaction is subject to Hart-Scott-Rodino antitrust review and is expected to close in Q3 2026.

For BMS, the deal is strategically significant in the context of the company’s patent cliff exposure and the need to refresh an early pipeline that has been under investor scrutiny. The arrangement gives BMS access to Hengrui’s expansive discovery infrastructure at a moment when Western pharmaceutical companies are increasingly recognising that Chinese biotechs are producing first-in-class and best-in-class biology at competitive speed. BioPharma Dive noted that the BMS-Hengrui alliance ranks as the second-largest China-out licensing agreement since the start of 2025, trailing only AstraZeneca’s $18.5 billion pact with CSPC in January 2026. The broader trend of Chinese pharma collaboration moving from asset-level licensing to full pipeline partnerships is one of the defining structural shifts in global drug development right now, and this deal accelerates that trajectory.

Source: Bristol Myers Squibb Official Press Release | https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-and-Hengrui-Pharma-Announce-Strategic-Agreements-to-Advance-Innovative-Medicines-Across-Oncology-Hematology-and-Immunology-2026-EbQpaI6Zdc/default.aspx

Source: STAT News | https://www.statnews.com/2026/05/12/bristol-myers-squibb-hengrui-china-licensing-deal/

FDA Commissioner Marty Makary Resigns, Kyle Diamantas Named Acting Head

Dr. Marty Makary resigned as FDA Commissioner on May 12, 2026, ending a turbulent 13-month tenure at the agency. President Trump confirmed the resignation and announced that Kyle Diamantas, previously the FDA’s deputy commissioner for food and a Trump-aligned attorney with no medical training, would step in as acting commissioner while a search for a permanent, Senate-confirmed replacement proceeds. The departure makes Makary the fourth senior Trump administration health official to leave in 2026.

Makary’s tenure at the FDA was marked by sustained instability. Multiple senior career officials departed during his leadership, some by resignation, others effectively forced out, creating what pharmaceutical industry observers described as a cycle of institutional knowledge loss at a time when the agency was simultaneously being asked to review an unprecedented volume of novel drug applications. He drew criticism from both directions: from Make America Healthy Again advocates who believed he was insufficiently aggressive in advancing the RFK Jr. agenda on food additives, vaccine policy, and obesity drug scrutiny, and from traditional industry and scientific stakeholders who objected to unpredictable regulatory decision-making and the perceived subordination of scientific standards to political interests. Makary himself highlighted achievements including speedier drug reviews, new guidance for psychedelics, a plausible mechanism pathway for rare disease approvals, and updated menopausal hormone replacement labeling.

The appointment of Diamantas carries its own set of concerns for drug developers, device manufacturers, and public health researchers. A non-scientist leading the FDA for any extended period creates a structural accountability gap that pharmaceutical companies, patient advocacy groups, and academic medical centers will need to track carefully. Several senior regulatory positions at the agency remain vacant or are held by acting officials, meaning the leadership structure overseeing drug, biologic, and device approvals is unusually thin. The drug development pipeline is dense, and the next permanent FDA commissioner will inherit an agency that needs both scientific credibility and administrative stabilisation in roughly equal measure.

Source: STAT News | https://www.statnews.com/2026/05/12/fda-commissioner-marty-makary-resigns-kyle-diamantas-acting/

Source: NPR | https://www.npr.org/2026/05/12/nx-s1-5819722/fda-commissioner-makary-resigns

England Launches First Cross-Government Mental Health Strategy in 15 Years

The UK Department of Health and Social Care launched a call for evidence on May 15, 2026, to shape what it described as a once-in-a-generation cross-government mental health strategy for England, the first comprehensive national plan of its kind since 2011. The strategy is embedded within England’s broader 10-Year Health Plan and is intended to drive a structural shift away from crisis-led care and toward earlier intervention, prevention, and sustained community-based support. Frontline clinicians, mental health practitioners, voluntary sector organisations, and individuals with lived experience are invited to submit evidence through July 10, 2026.

The backdrop against which this strategy arrives is sobering. Approximately one in five adults in England is now living with a common mental health condition, and rates of mental health problems among children and young people have roughly doubled over the past two decades. NHS mental health spending for the 2026-27 financial year is forecast to reach a record £16.1 billion, a real-terms increase of approximately £140 million on the prior year, and the government confirmed that its target to recruit 8,500 additional mental health workers has been met three years ahead of schedule. A further £473 million has been committed over the following four years to expand school-based mental health support teams, community provision, and emergency care capacity, with mental health support teams in schools on track to reach 100% national coverage by 2029.

The strategy’s arrival has been broadly welcomed by sector organisations, though health policy analysts at the Centre for Mental Health cautioned that welcome intent must be matched by concrete implementation architecture. The call for evidence consultation period is eight weeks, relatively brief for a strategy that will cover children, adults, and older people across a fragmented system involving the NHS, local government, employers, schools, and the justice system. What clinicians and commissioners will be watching closely is whether the final strategy provides funding formulae and commissioning standards capable of reducing the postcode lottery in mental health access that has persisted despite years of policy attention. For health system investors and digital mental health companies, the strategy signals sustained government appetite for scalable, community-based solutions, particularly platforms that can extend reach without proportionate workforce cost.

Source: UK Government Official Announcement | https://www.gov.uk/government/news/government-to-transform-mental-health-care-with-new-strategy

Source: Department of Health and Social Care Call for Evidence | https://www.gov.uk/government/calls-for-evidence/informing-the-mental-health-strategy-for-england/informing-the-mental-health-strategy-for-england-call-for-evidence-document

Full-Life Technologies Closes $150 Million Series D for Radiopharmaceutical Pipeline

Full-Life Technologies, a fully integrated radiopharmaceuticals company with operations in Suzhou, China and Gembloux, Belgium, announced on May 18, 2026 the completion of a $150 million financing package. The round comprises approximately $110 million in Series D equity, led by Vivo Capital with participation from SK Biopharmaceuticals, Chengwei Capital, HSG, Junson Capital, and several other institutional investors, alongside $40 million in debt financing. With this close, Full-Life has raised nearly $350 million in total funding since its founding in 2021.

The capital will primarily advance two clinical-stage programs: [225Ac]-FL-020, a potential best-in-class actinium-225 radiotherapeutic targeting prostate cancer, and [225Ac]-FL-261, a potential first-in-class candidate being evaluated across multiple solid tumor indications. Both assets emerged from Full-Life’s proprietary UniRDC discovery platform. A significant portion of the proceeds is designated for completing the company’s Good Manufacturing Practice-grade actinium-225 manufacturing facility in Belgium, a strategically critical investment given that isotope supply remains one of the most acute bottlenecks in the global radiopharmaceutical sector. Full-Life expects to have three differentiated clinical-stage programs operational by the end of 2026.

The timing is notable. Radiopharmaceuticals have become one of the most heavily capitalised areas in oncology drug development, driven by the clinical success of Novartis’s Lutathera and Pluvicto, Eli Lilly’s acquisition of Point Biopharma, and AstraZeneca’s $2.4 billion acquisition of Fusion Pharmaceuticals in 2024. Full-Life’s Belgium manufacturing position is a genuine differentiator, since actinium-225 production capacity globally is severely constrained and control over the supply chain will become increasingly decisive as more alpha-emitting radiopharmaceutical programs reach late-stage development. The company’s dual clinical focus, prostate cancer, where the radiopharmaceutical evidence base is strongest, and broader solid tumors, gives it both near-term regulatory optionality and longer-term platform upside. Announced on the same day, Accro Bioscience, a Chinese immunology-focused biotech, separately raised $50 million in a Series C led by OrbiMed to fund a Phase 2b trial of its RIPK2 inhibitor AC-101 in ulcerative colitis, with earlier studies conducted in both China and Australia.

Source: Full-Life Technologies Official Press Release | https://www.prnewswire.com/news-releases/full-life-technologies-announces-us150-million-financing-to-accelerate-multiple-clinical-stage-assets-and-manufacturing-capabilities-302774873.html

Revolution Medicines Confirms Phase 3 Win for Daraxonrasib in Pancreatic Cancer

Revolution Medicines announced on May 21, 2026 that it would host an investor webcast on May 31 to present detailed data from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The company had disclosed positive topline results in April 2026, revealing that daraxonrasib, an oral, once-daily RAS(ON) multi-selective inhibitor, met all primary and key secondary endpoints in the randomized, controlled global trial. In the overall intent-to-treat population, the drug delivered a median overall survival of 13.2 months compared with 6.7 months for standard-of-care intravenous chemotherapy, representing a hazard ratio of 0.40 and a statistically and clinically meaningful p-value of less than 0.0001.

The detailed data will be presented in a Plenary Session at the 2026 ASCO Annual Meeting in Chicago on May 31, with principal investigator Brian M. Wolpin, MD, MPH of Dana-Farber Cancer Institute presenting. The NEJM had already published Phase 1/2 data on daraxonrasib in early May 2026, providing the mechanistic and early clinical context for the Phase 3 results. Revolution Medicines has stated its intention to submit a New Drug Application to the FDA, potentially utilizing the Commissioner’s National Priority Voucher program for accelerated review.

Pancreatic cancer has resisted systemic therapy advances for decades, and the RAS oncogene was long considered structurally intractable as a drug target. The Phase 3 survival data from RASolute 302, nearly doubling median overall survival against chemotherapy, represents a threshold that will reshape how oncologists, payers, and guideline committees think about KRAS-targeting in PDAC. If approved, daraxonrasib would become the first RAS inhibitor to demonstrate registrational-level survival benefit in this disease setting, a milestone that carries implications far beyond pancreatic cancer alone. Competing programs from Immuneering and Actuate Therapeutics are in earlier development, and the clinical and commercial pressure on those programs will be significant once full ASCO data enter the public record.

Source: Revolution Medicines Press Release | https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-present-pivotal-phase-3-rasolute-302

Source: New England Journal of Medicine Publication | https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-publication-new-england-journal

UK Government Launches Fit Note Reform Pilots Covering 100,000 Appointments

The UK Department of Work and Pensions and Department of Health and Social Care jointly announced on May 20, 2026 the launch of fit note reform pilots across four NHS WorkWell integrated care board sites in England. The pilots, backed by £3 million in first-year funding, will cover up to 100,000 appointments over a 12-month period and test two distinct alternative models. At the Birmingham and Solihull, and Coventry and Warwickshire sites, GPs will continue to issue initial fit notes but follow-up support will be provided by community health workers and non-clinical practitioners. At the Cornwall and the Isles of Scilly, and Lancashire and South Cumbria sites, GPs will refer patients directly to support services without issuing a fit note at all.

The policy context is significant. Currently, approximately 11 million fit notes are issued in England every year, with more than 90% declaring the patient entirely not fit for work. The government’s call for evidence results, also published on May 21, revealed that only 29% of primary care healthcare professionals viewed issuing fit notes as a meaningful use of their time, while roughly 60% of employers reported that the system provided no useful guidance on workplace adjustments or phased return. The British Medical Association contributed to the pilot design and expressed cautious support, while occupational health specialists broadly welcomed the shift toward personalised return-to-work planning.

The reform is best understood as an early signal of the government’s broader ambition to reduce economic inactivity caused by long-term sickness, a policy priority directly tied to the Treasury’s productivity agenda. The intersection of workforce health, NHS capacity, and employer engagement makes this pilot consequential beyond its relatively modest initial budget. For health systems and occupational health providers, the pilots create both an evidence-generation opportunity and a potential commissioning model that could scale nationally if the trial data support it. Employers are watching closely: the trials will test whether three-way conversations between employees, healthcare workers, and managers from the first day of absence can keep people connected to work in ways that the paper-based fit note system has consistently failed to do.

Source: UK Government Official Press Release | https://www.gov.uk/government/news/broken-fit-note-system-to-be-overhauled

Source: Fit Note Reform Call for Evidence Results | https://www.gov.uk/government/publications/fit-note-reform-call-for-evidence-results

Relay Therapeutics Posts Phase 2 Data for Zovegalisib in Rare Vascular Disorders

Relay Therapeutics announced on May 19, 2026 initial Phase 2 data from the ReInspire trial evaluating zovegalisib, its investigational mutant-selective PI3Kα inhibitor, in patients with PIK3CA-driven vascular anomalies. The data were presented at the 2026 International Society for the Study of Vascular Anomalies World Congress in Philadelphia. Vascular anomalies are rare disorders involving abnormal development of blood, lymphatic, and surrounding tissue vasculature, a group of conditions affecting an estimated 170,000 Americans, for whom no approved systemic therapy currently exists.

The Phase 2 results drew immediate positive commentary from Wall Street analysts, with BioSpace reporting that the response rates exceeded expectations and that zovegalisib’s PI3Kα mutant-selective mechanism appeared to offer a differentiated safety profile suited to chronic dosing. Relay’s President of R&D, Don Bergstrom, described the results as the first demonstration of PI3Kα mutant-selective inhibition’s promise in vascular anomalies, citing robust volumetric responses and symptomatic improvement alongside a manageable safety signal. PIK3CA mutations are the most frequently identified driver across both vascular anomalies and cancer biology, making zovegalisib’s potential cross-indication utility a key element of Relay’s R&D thesis.

For rare disease patients and their families, this data represents genuine clinical progress in a therapeutic area that has received minimal pharmaceutical investment. The absence of approved systemic options for conditions such as PIK3CA-related overgrowth spectrum and venous malformations has left patients reliant on procedural interventions that address symptoms without targeting the underlying mutation. Relay faces competition from Celcuity’s gedatolisib in certain overlapping PI3Kα contexts, and both companies will be moving toward late-stage development with the ASCO-era competitive intelligence environment shaping investor and clinician expectations. The key question for Relay’s regulatory strategy will be whether the FDA’s accelerated approval pathway for rare diseases can be accessed based on volumetric response as a surrogate endpoint, which would meaningfully shorten the timeline to patient access.

Source: Relay Therapeutics Official Press Release | https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-initial-clinical-data-0

Source: Fierce Biotech | https://www.fiercebiotech.com/biotech/relay-full-steam-ahead-pi3k-inhibitor-fueled-first-data-blood-vessel-disorders

Eli Lilly’s Oral GLP-1 Foundayo Reshapes Obesity Treatment Access

Eli Lilly’s Foundayo (orforglipron), approved by the FDA on April 1, 2026, continued to reshape the obesity pharmacotherapy landscape through the May 16-23 period as the drug became broadly available through US retail pharmacies and telehealth providers. Foundayo is an oral, once-daily small molecule GLP-1 receptor agonist that can be taken at any time of day without restrictions on food or water intake, a meaningful practical advantage over oral semaglutide, which requires a 30-minute fasting window before and after administration.

Data from the pivotal ATTAIN-1 trial, which enrolled more than 4,500 patients, showed that adults with overweight or obesity achieved weight loss of 7.8% with the 6 mg dose, 9.3% with 12 mg, and 12.4% with the 36 mg dose over 72 weeks, figures that trail the 20%-plus reductions seen with injectable GLP-1 therapies but that significantly expand the treatment’s accessibility profile. Lilly is pricing Foundayo at $25 per month for commercially insured patients and $149 per month for self-pay individuals, with Medicare Part D patients accessing the drug at $50 per month, pricing that creates a lower cost-of-entry point relative to injectable alternatives and is likely to accelerate uptake in populations who had been deterred by injection administration or the cost of higher-priced branded injectables.

The competitive and public health implications are substantial. Fewer than one in ten people who could clinically benefit from a GLP-1 receptor agonist are currently receiving one, and the barriers most frequently cited are cost, administration complexity, perceived stigma, and access constraints in primary care. An affordable oral option with no administration timing restrictions removes at least two of those barriers simultaneously. The ATTAIN Phase 3 clinical program enrolled more than 4,500 participants across obesity management studies, and Lilly has filed separately for orforglipron in type 2 diabetes based on the ACHIEVE trial program. For competing manufacturers, the oral GLP-1 entry creates immediate pressure to differentiate on efficacy, duration of effect, or cardiovascular outcome data, areas where the injectable market leaders still hold an evidence advantage.

Source: Eli Lilly Official Press Release | https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

TGA Alerts Australia on ANDEXXA Removal and Peptide Product Safety Risks

Australia’s Therapeutic Goods Administration issued two notable regulatory alerts during the May 16-23 period. On May 21, 2026, the TGA confirmed that ANDEXXA, a recombinant modified human factor Xa protein used to reverse anticoagulation in patients receiving factor Xa inhibitors such as rivaroxaban or apixaban, is no longer provisionally approved for use in Australia and has been removed from the Australian Register of Therapeutic Goods (ARTG). The decision carries clinical implications for emergency departments and critical care units across the country, where ANDEXXA had been used in life-threatening bleeding situations in anticoagulated patients.

Separately, the TGA published a consumer warning highlighting the risks associated with importing and using unapproved peptide products promoted online, including growth hormone-releasing peptides, melanotan variants, and related compounds. The warning specifically addressed products distributed through online pharmacies and social media channels and recommended that Australians seek guidance from registered healthcare professionals before using any therapeutically active substance not registered on the ARTG.

For Australian hospital pharmacists, the ANDEXXA withdrawal requires immediate protocol review across cardiac and stroke units where anticoagulated patients may require emergency reversal. Alternative reversal agents exist, Praxbind (idarucizumab) covers dabigatran reversal, and supportive care remains the primary option for factor Xa inhibitor reversal in centres without ANDEXXA, but the loss of a registered reversal option in a market with high anticoagulation use among an aging population is a genuine patient safety concern. The Australian Medical Association’s president update for the week also addressed digital health developments and the country’s diphtheria situation, reflecting the continued breadth of regulatory and public health pressures facing Australian healthcare administrators. The TGA’s peptide warning, meanwhile, fits within a global pattern of regulatory crackdowns on the unregulated peptide market, which has expanded significantly through online channels despite known risks of contamination, dosing inaccuracy, and systemic adverse effects.

Source: TGA Official Website | https://www.tga.gov.au/therapeutic-goods-administration-tga

Source: Australian Medical Association News | https://www.ama.com.au/news

Comparative Data: Key Healthcare Developments at a Glance, May 16–23, 2026

Closing

The week of May 16 to 23, 2026, underscored how deeply interconnected regulatory stability, clinical science, and health policy have become as drivers of patient outcomes across global health systems. From the FDA’s leadership vacuum following Makary’s resignation to the UK’s structural NHS overhaul and England’s mental health reckoning, the institutions that underpin drug development and care delivery are themselves in flux, a condition that clinicians, investors, and patients cannot afford to ignore.

Watch for the ASCO Plenary presentation of daraxonrasib’s full Phase 3 data on May 31, the parliamentary progress of the UK Health Bill through its committee stages, and the next regulatory decision on Enhertu’s Project Orbis applications across the European Medicines Agency and Health Canada. Stay tuned for more of the latest healthcare news as these storylines develop across global health systems.